Bristol Myers Squibb: Aggressive M&A, riskier strategy to solve growth problem (BMY)


I am a month ago believed that Bristol Myers Squibb (NYSE:BMY) she found herself in a tough but cheap spot. The company faces headwinds and challenges related to the loss of exclusivity of one of its best-selling drugs, Revlimid, and upcoming expirations